A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Items 501–600 of 1,018
Cyclodextrins in drug delivery systems
Otero-Espinar, F. J., Torres-Labandeira, J. J., Alvarez‐Lorenzo, C., & Blanco-Méndez, J. (2010) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(10)50046-7 · Cited by 132
Hu, J., Rogers, T. L., Brown, J., Young, T., Johnston, K. P., & Williams, R. O. (2002) · Pharmaceutical Research · doi:10.1023/a:1020390422785 · Cited by 122
“Of particular interest is the poorly water soluble, highly permeable APIs discussed in the Biopharmaceutics Classification System (BCS Class II) (1), such as dana- zol and carbamazepine.”
BackgroundFood, physiology and drug delivery
Varum, F., Hatton, G. B., & Basit, A. W. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.034 · Cited by 131
Perucca, E., Bialer, M., & White, H. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01027-2 · Cited by 127
“6 [86, 87], cenobamate can be classified as Biopharmaceutics Classification System Class 1, namely as a highly water-soluble and highly permeable compound [88], as well as Biopharmaceutics Drug Disposition Classification System Class 1, namely, as a highly water-soluble compoound that is eliminated by metabolism in hu…”
BackgroundCyclodextrins and the Biopharmaceutics Classification System of Drugs
Loftsson, Þ. (2002) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1023/a:1023088423667 · Cited by 145
Six, K., Berghmans, H., Leuner, C., Dressman, J., Werde, K. V., Mullens, J., Benoist, L., Thimon, M., Meublat, L., Verreck, G., et al. (2003) · Pharmaceutical Research · doi:10.1023/a:1024414423779 · Cited by 120
“According to the Biopharmaceutics Classification System ( 3 ), it can be classified as a class II compound.”
MethodProdrugs of triterpenoids and their derivatives
Zhou, M., Zhang, R., Wang, M., Xu, G., & Liao, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.005 · Cited by 120
Iyer, R. M., Jovanovska, V. P., Berginc, K., Jaklič, M., Fabiani, F., Harlacher, C., Huzjak, T., & Sánchez-Félix, M. V. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101682 · Cited by 120
“predict oral absorption based on the aqueous solubility and permeability of a drug [1,2].”
BackgroundKomura, H., Watanabe, R., & Mizuguchi, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112619 · Cited by 144
“The significance of these two parameters can be demonstrated by the fact that the maximum absorbable dose is mainly dependent on water solubility and absorption rate constants, when the intestinal water volume is fixed [14,15].”
BackgroundEffect of Crystal Size on the In Vitro Dissolution and Oral Absorption of Nitrendipine in Rats
Xia, D., Cui, F., Piao, H., Cun, D., Piao, H., Jiang, Y., Ouyang, M., & Quan, P. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0200-0 · Cited by 133
“They also proposed a biopharmaceutics classification system (BCS) in which drugs are classified into four groups according to their permeability and solubility (3, 4 ).”
BackgroundComputational methodology for solubility prediction: Application to the sparingly soluble solutes
Li, L., Totton, T. S., & Frenkel, D. (2017) · The Journal of Chemical Physics · doi:10.1063/1.4983754 · Cited by 127
Co-former selection for co-amorphous drug-amino acid formulations
Kasten, G., Löbmann, K., Grohganz, H., & Rades, T. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.036 · Cited by 119
Okumu, A., Maso, M. D., & Löbenberg, R. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.10.019 · Cited by 120
Sunesen, V. H., Vedelsdal, R., Kristensen, H. G., Christrup, L. L., & Müllertz, A. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.11.005 · Cited by 119
Solubilities of Pharmaceutical Compounds in Ionic Liquids
Smith, K. B., Bridson, R. H., & Leeke, G. A. (2011) · Journal of Chemical & Engineering Data · doi:10.1021/je101040p · Cited by 119
Maniruzzaman, M., Rana, M., Boateng, J. S., Mitchell, J. C., & Douroumis, D. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.670642 · Cited by 118
Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them
Sosnik, A., & Augustine, R. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.022 · Cited by 133
Pavan, B., Dalpiaz, A., Marani, L., Beggiato, S., Ferraro, L., Canistro, D., Paolini, M., Vivarelli, F., Valerii, M. C., Comparone, A., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00018 · Cited by 127
Current Trends on Solid Dispersions: Past, Present, and Future
Malkawi, R., Malkawi, W. I., Al-Mahmoud, Y., & Tawalbeh, J. H. (2022) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2022/5916013 · Cited by 118
“As a result, solid disperion technology has many promises to enhance the oral absorption of BCS Class II drugs and thier bioavailability [7].”
BackgroundInfluentialPrediction of pharmacokinetic properties using experimental approaches during early drug discovery
Chaturvedi, P. R., Decker, C. J., & Odinecs, A. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00228-3 · Cited by 133
Behrens, I., & Kissel, T. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00146-5 · Cited by 117
Alhalaweh, A., Roy, L. P., Rodríguez‐Hornedo, N., & Velaga, S. P. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300189b · Cited by 117
Silva, A. C., Kumar, A., Wild, W., Ferreira, D., Santos, D. F. G., & Forbes, B. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.058 · Cited by 132
Bou‐Chacra, N. A., Melo, K. J. C., Morales, I. A. C., Stippler, E. S., Kesisoglou, F., Yazdanian, M. A., & Löbenberg, R. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0085-5 · Cited by 122
“The drug substance will then dissolve instantly after administration (122,123).”
BackgroundProdrugs of bisthiazolium salts are orally potent antimalarials
Vial, H. J., Wein, S., Farenc, C., Kocken, C. H. M., Nicolas, O., Ancelin, M., Bressolle, F., Thomas, A. W., & Calas, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404037101 · Cited by 117
Avdeef, A., & Tsinman, O. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9679-z · Cited by 117
The Utility of Sulfonate Salts in Drug Development
Elder, D. P., Delaney, E., Teasdale, A. J., Eyley, S., Reif, V. D., Jacq, K., Facchine, K. L., Oestrich, R. S., Sandra, P., & David, F. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22058 · Cited by 117
Dahan, A., & Amidon, G. L. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00102.2009 · Cited by 121
“According to the Biopharmaceutics Classification System (BCS) principles, all compounds are classified into one of four biopharmaceutical classes according to their water solubility and membrane permeability characteristics (1, 3, 17).”
Self-citationPocock, K., Delon, L., Bala, V., Rao, S., Priest, C., Prestidge, C., & Thierry, B. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00023 · Cited by 111
Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs
Mohite, P. B., Singh, S. K., Pawar, A. R., Sangale, A., & Prajapati, B. G. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1232012 · Cited by 121
“Because of these two conditions, oral medicine bioavailability is decreased (Amidon et al., 1995).”
Prediction of human intestinal permeability using artificial membrane permeability
Sugano, K., Nabuchi, Y., Machida, M., & Aso, Y. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00161-3 · Cited by 116
Gut instincts: CYP3A4 and intestinal drug metabolism
Thummel, K. E. (2007) · Journal of Clinical Investigation · doi:10.1172/jci34007 · Cited by 117
Ternary systems of naproxen with hydroxypropyl-β-cyclodextrin and aminoacids
Mura, P. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00265-5 · Cited by 116
Sachs‐Barrable, K., Thamboo, A., Lee, S. D., & Wasan, K. M. (2007) · PubMed · Cited by 142
Development and Evaluation of Glyburide Fast Dissolving Tablets Using Solid Dispersion Technique
Valleri, M., Mura, P., Maestrelli, F., Cirri, M., & Ballerini, R. (2004) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120037483 · Cited by 115
“However, poorly water-soluble drugs, when administered orally, have been shown to be slowly and unpredictably absorbed since their bioavailability is largely dependent on the dissolution process in the gastrointestinal tract.([1]) Glyburide is an oral hypoglycemic agent whose low aqueous solubility gives rise to unsat…”
BackgroundImpact of Polymers on Crystal Growth Rate of Structurally Diverse Compounds from Aqueous Solution
Ilevbare, G. A., Liu, H., Edgar, K. J., & Taylor, L. S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400029v · Cited by 132
Correlation between Molecular Mobility and Physical Stability of Amorphous Itraconazole
Bhardwaj, S. P., Arora, K. K., Kwong, E. C., Templeton, A. C., Clas, S., & Suryanarayanan, R. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300487u · Cited by 115
Food effects on tablet disintegration
Abrahamsson, B., Albery, T., Eriksson, A., Gustafsson, I., & Sjöberg, M. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(04)00064-8 · Cited by 115
Hastedt, J. E., Bäckman, P., Clark, A. R., DOUB, W. H. J., Hickey, A. J., Hochhaus, G., Kuehl, P. J., Lehr, C., Mauser, P. J., McConville, J. T., et al. (2016) · AAPS Open · doi:10.1186/s41120-015-0002-x · Cited by 125
Benet, L. Z. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00498.x · Cited by 116
What is modulating solubility in simulated intestinal fluids?
Ottaviani, G., Gosling, D. J., Patissier, C., Rodde, S., Zhou, L., & Faller, B. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.07.012 · Cited by 126
The Critical Role of Passive Permeability in Designing Successful Drugs
Di, L., Artursson, P., Avdeef, A., Benet, L. Z., Houston, J. B., Kansy, M., Kerns, E. H., Lennernäs, H., Smith, D. A., & Sugano, K. (2020) · ChemMedChem · doi:10.1002/cmdc.202000419 · Cited by 119
Self-citationLow Dose Lipid Formulations: Effects on Gastric Emptying and Biliary Secretion
Kossena, G. A., Charman, W. N., WILSON, C. G., O’Mahony, B., Lindsay, B., Hempenstall, J., Davison, C. L., Crowley, P., & Porter, C. J. H. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9363-8 · Cited by 128
“However, the high affinity of poorly water-soluble drugs (PWSD) for these colloidal species (21–23) also dictates that this physiological response may be of great benefit in increasing the apparent intestinal solubility of drugs where low water-solubility is a barrier to efficient absorption ( 24 ).”
BackgroundFDA Critical Path Initiatives: Opportunities for Generic Drug Development
Lionberger, R. A. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9010-2 · Cited by 114
“There was little discussion of these issues at the May 2007 AAPS BE, BCS and Beyond workshop.”
MethodInfluentialFofaria, N. M., Qhattal, H. S. S., Liu, X., & Srivastava, S. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.11.045 · Cited by 114
“In fact, for poorly water-soluble drug such as PL, the rate and extent of dissolution dictates the absorption rate from the gastrointestinal tract (Amidon et al., 1995).”
BackgroundHydrogen bonding descriptors in the prediction of human in vivo intestinal permeability
Winiwarter, S., Ax, F., Lennernäs, H., Hallberg, A., Pettersson, C. E., & Karlén, A. (2002) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(02)00163-8 · Cited by 114
Self-citationRouge, N., Allémann, É., Gex‐Fabry, M., Balant, L., Cole, E. T., Buri, P. A., & Doelker, É. (1998) · Pharmaceutica Acta Helvetiae · doi:10.1016/s0031-6865(97)00050-2 · Cited by 113
Yang, W. P., Tam, J. M., Miller, D. A., Zhou, J., McConville, J. T., Johnston, K. P., & Williams, R. O. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.05.003 · Cited by 112
Woo, J. S., Song, Y., Hong, J.-Y., Lim, S., & Kim, C. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.11.001 · Cited by 112
Evaluation of Griseofulvin Binary and Ternary Solid Dispersions with HPMCAS
Al-Obaidi, H., & Buckton, G. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9319-x · Cited by 112
“Griseofulvin is also classified as class II drug according to its solubility and absorption profile (low solubility with good absorption through the gut) ( 4 ).”
BackgroundTsume, Y., Langguth, P., García‐Arieta, A., & Amidon, G. L. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1800 · Cited by 112
“5 [3-4].”
Self-citationBerthelsen, R., Klitgaard, M., Rades, T., & Müllertz, A. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.010 · Cited by 111
Shilling, A. D., Nedza, F. M., Emm, T., Diamond, S., McKeever, E., Punwani, N., Williams, W., Arvanitis, A., Galya, L. G., Li, M., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033787 · Cited by 111
“Amidon et al. (1995) have proposed a biopharmaceutical classification system that bins drugs into four classes based on solubility and dissolution and permeability and absorption.”
BackgroundKetoconazole Salt and Co-crystals with Enhanced Aqueous Solubility
Martin, F., Pop, M. M., Borodi, G., Filip, X., & Kacsó, I. (2013) · Crystal Growth & Design · doi:10.1021/cg400638g · Cited by 111
Amino Acids in the Development of Prodrugs
Vale, N., Ferreira, A., Matos, J., Fresco, P., & Gouveia, M. J. (2018) · Molecules · doi:10.3390/molecules23092318 · Cited by 124
“Also, solubility and permeability interactions and their impact on intestinal drug absorption are most prominently described by the Biopharmaceutics Classification System (BCS) [15].”
BackgroundLeane, M. M., Pitt, K. G., Reynolds, G., Dawson, N., Ziegler, I., Szepes, A., Crean, A. M., Agnol, R. D., & Sy, T. M. C. (2018) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2018.1534863 · Cited by 111
“Nevertheless, evaluating the compounds’ actual dose numbers (D0) (Amidon et al. 1995), differences can be observed between those BCS II compounds.”
BackgroundToward anIn VivoDissolution Methodology: A Comparison of Phosphate and Bicarbonate Buffers
Sheng, J. J., McNamara, D. P., & Amidon, G. L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800148u · Cited by 111
Self-citationPharmacokinetic aspects and in vitro–in vivo correlation potential for lipid-based formulations
Kollipara, S., & Gandhi, R. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.09.001 · Cited by 122
Heimbach, T., Suarez‐Sharp, S., Kakhi, M., Holmstock, N., Olivares-Morales, A., Pepin, X. J. H., Sjögren, E., Tsakalozou, E., Seo, P., Li, M., et al. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0298-x · Cited by 110
Is prodrug design an approach to increase water solubility?
Sanches, B. M. A., & Ferreira, E. I. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118498 · Cited by 116
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Araújo, D. V., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., Bono, J. S. D., Drilon, A. E. D. C., Garralda, E., Ivy, P. S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.158 · Cited by 115
Basavaraj, S., & Betageri, G. V. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.12.003 · Cited by 133
Alsenz, J., & Haenel, E. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000008043.71001.43 · Cited by 110
“Permeability values, SD, and BCS classification of several other test compounds after 1 week were comparable to those obtained after 3 weeks in the traditional and in the 96-well Caco-2 systems.”
MethodInfluentialPrediction of Intestinal Drug Absorption Properties by Three-Dimensional Solubility Parameters
Breitkreutz, J. (1998) · Pharmaceutical Research · doi:10.1023/a:1011941319327 · Cited by 110
Moes, J. J., Koolen, S. L. W., Huitema, A. D. R., Schellens, J. H. M., Beijnen, J. H., & Nuijen, B. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.041 · Cited by 109
Transdermal delivery of nobiletin using ionic liquids
Hattori, T., Tagawa, H., Inai, M., Kan, T., Kimura, S.-I., Itai, S., Mitragotri, S., & Iwao, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-56731-1 · Cited by 109
Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems
Park, H., Ha, E., & Kim, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040365 · Cited by 127
How to manage a high-output stoma
Nightingale, J. M. D. (2021) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101108 · Cited by 110
Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate
Ambrogi, V., Perioli, L., Marmottini, F., Giovagnoli, S., Esposito, M., & Rossi, C. R. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.07.005 · Cited by 109
den Mooter, G. V., Weuts, I., Ridder, T. D., & Blaton, N. M. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.02.025 · Cited by 109
Konsoula, R., & Jung, M. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.05.001 · Cited by 108
“The biopharmaceutics classification system (BCS) outlines the parameters for predicting bioavailability of drugs based on their aqueous solubility and intestinal permeability (Amidon et al., 1995; Kasim et al., 2004).”
BackgroundLöbenberg, R., Krämer, J., Shah, V. P., Amidon, G. L., & Dressman, J. (2000) · Pharmaceutical Research · doi:10.1023/a:1007529020774 · Cited by 108
“II In vitro optimization of screened variThis is consistent with the FDA guideline for IR products i.e. ables on ER-coated spheres for the establishment of an in vitro/ “for slowly dissolving or poorly water soluble drugs (BCS case in vivo correlation.”
InfluentialSelf-citationKuentz, M., Nick, S., Parrott, N. J., & Röthlisberger, D. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.08.011 · Cited by 108
Development of predictive pharmacokinetic simulation models for drug discovery
Norris, D. A., Leesman, G. D., Sinko, P. J., & Grass, G. M. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00232-1 · Cited by 108
Fuchs, A., & Dressman, J. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24183 · Cited by 118
Tarral, A., Blesson, S., Mordt, O. V., Torreele, E., Sassella, D., Bray, M. A., Hovsepian, L., Evène, E., Gualano, V., Felices, M., et al. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0136-3 · Cited by 107
“Creatinine elevations had also been observed in Study 1C and, as no other abnormalities in renal parameters were observed, they were considered likely to be related to the drug class [19].”
BackgroundResultLacerda, L., Parize, A. L., Fávere, V. T., Laranjeira, M. C. M., & Stulzer, H. K. (2014) · Materials Science and Engineering C · doi:10.1016/j.msec.2014.01.054 · Cited by 115
“In the BCS rifampicin is considered to be a borderline class II drug, where the rate and extent of dissolution are critical for obtaining optimum bioavailability [35].”
BackgroundSarode, A. L., Wang, P., Obara, S., & Worthen, D. R. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.10.005 · Cited by 107
“Such compounds with low solubility and high permeability are categorized as Class II drugs according to the Biopharmaceutical Classification System (BCS) [5].”
BackgroundBeig, A., Miller, J. M., & Dahan, A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.02.012 · Cited by 114
“[1], the solubility of the drug dose in the aqueous intestinal milieu and its permeability through the intestinal membrane are the two key parameters governing the absorption following oral administration [2–4].”
BackgroundSalt form selection and characterization of LY333531 mesylate monohydrate
Engel, G. L., Farid, N. A., Faul, M. M., Richardson, L. A., & Winneroski, L. L. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00350-1 · Cited by 107
Zhang, K., Yu, H., Luo, Q., Yang, S., Lin, X., Zhang, Y. X., Tian, B., & Tang, X. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.03.002 · Cited by 106
Elgart, A., Cherniakov, I., Aldouby, Y., Domb, A. J., & Hoffman, A. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1063-y · Cited by 111
Determination of aqueous solubility by heating and equilibration: A technical note
Loftsson, Þ., & Hreinsdóttir, D. (2006) · AAPS PharmSciTech · doi:10.1208/pt070104 · Cited by 106
Nugent, M., & Higginbotham, C. L. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.02.014 · Cited by 113
Chiu, Y.-Y., Higaki, K., Neudeck, B. L., Barnett, J. L., Welage, L. S., & Amidon, G. L. (2003) · Pharmaceutical Research · doi:10.1023/a:1023481418576 · Cited by 106
“The implications of the overall effects of surfactants on the permeability of CsA indicate that CsA could be classified as a BCS Class II lowsolubility, high-permeability drug (25).”
BackgroundSelf-citationLennernäs, H. (1995) · Pharmaceutical Research · doi:10.1023/a:1016220428705 · Cited by 106
Self-citationOral Absorption, Intestinal Metabolism and Human Oral Bioavailability
El-Kattan, A., & Varm, M. (2012) · Topics on Drug Metabolism · doi:10.5772/31087 · Cited by 102
“Based on these properties Amidon et al. proposed biopharmaceutic classification system (BCS), which in present times is serving as a guide for regulatory and industrial purposes (Amidon et al. 1995).”
Drug delivery: an odyssey of 100 years
Pillai, O., Dhanikula, A. B., & Panchagnula, R. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00226-x · Cited by 105
Dahan, A., Sabit, H., & Amidon, G. L. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028282 · Cited by 110
“We showed previously that according to the biopharmaceutics classification system (Amidon et al., 1995), colchicine is a class III drug, i.”
BackgroundSelf-citationNikolakakis, I., & Partheniadis, I. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9040050 · Cited by 104
Yadav, P., Rastogi, V., & Verma, A. K. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00023-3 · Cited by 111
“lead to inadequate dissolution in the gastric milieu after oral administration which eventually show low bioavailability and thus suboptimal efficacy [1, 2].”
BackgroundNanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets
Lai, F., Pini, E., Angioni, G., Manca, M. L., Perricci, J., Sinico, C., & Fadda, A. M. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.07.005 · Cited by 105
Simulation models to predict oral drug absorption from in vitro data
Grass, G. M. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00436-x · Cited by 118
Shah, T. J., Amin, A. F., Parikh, J. R., & Parikh, R. H. (2007) · AAPS PharmSciTech · doi:10.1208/pt0802029 · Cited by 119
“The sparingly water-soluble drugs often show an erratic dissolution profile in gastrointestinal fluids, which consequently results in variable oral bioavailability.(1) To improve the dissolution and bioavailability of sparingly soluble drugs, researchers have employed various techniques, such as micronization, solubil…”
BackgroundHens, B., Corsetti, M., Spiller, R. E., Marciani, L., Vanuytsel, T., Tack, J. F., Talattof, A., Amidon, G. L., Koziolek, M., Weitschies, W., et al. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.11.063 · Cited by 113
“Acetaminophen is classified as a highly soluble and highly permeable drug (BCS class 1) (Amidon et al., 1995).”
BackgroundSelf-citationSmart nanomaterials in pharmaceutical analysis
Sharma, D., & Hussain, C. M. (2018) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2018.11.007 · Cited by 114
Solubility enhancement and application of cyclodextrins in local drug delivery
Kim, D., Lee, S., Pyo, Y.-C., Tran, P., & Park, J. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-019-00434-2 · Cited by 110
“The Biopharmaceutics Classification System (BCS) classifies drugs and drug candidates into four classes according to their solubilities and permeability characteristics (Amidon et al. 1995; Dressman et al. 1998; Yu et al. 2002).”
Fink, C., Sun, D. D., Wagner, K., Schneider, M., Bauer, H., Dolgos, H., Mäder, K., & Peters, S. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1672 · Cited by 112
“Additionally, the dose number (Do) was calculated to confirm whether the highest clinical dose (M0) can be completely dissolved in 250 mL intestinal fluid according to Amidon et al.3 with Eq.”
MethodNanomedicine for increasing the oral bioavailability of cancer treatments
Parodi, A., Buzaeva, P., Nigovora, D., Baldin, A. V., Kostyushev, D. S., Chulanov, V., Savvateeva, L. V., & Zamyatnin, A. A. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01100-2 · Cited by 108
Moseson, D. E., Bien, T. T., Karunakaran, B., Ambardekar, R., & Hiew, T. N. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100259 · Cited by 117
“Other classification systems have been used to trend aqueous solubility and permeability or metabolism as predictors of drug absorption (Amidon et al., 1995; Butler and Dressman, 2010; Rosenberger et al., 2018; Wu and Benet, 2005).”
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.